Extended Data Fig. 4: Gene-drug correlation in organoids.
From: Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer
a, A volcano plot representation of MANOVA incorporating drug sensitivity and genetic mutations. Each dot indicates a genetic mutation-drug pair. Statistically significant pairs (TP53 mutation/nutlin-3 and TP53 mutation/paclitaxel pairs, FDR < 0.25) are highlighted in blue. b, The response of CRC18a (TP53-mutant) and CRC18b (TP53-wild type) to nutlin-3. The organoids are subclones that were derived from the same tumor. Data are shown as mean ± SD. n = 3 c, Capillary-based immunodetection of p53 in CRC18a and CRC18b with or without nutlin-3 treatment. d, IC50 values of EGFR inhibitors and RTK/MAPK pathway mutations in a refined screening condition. The organoids were treated with the indicated drugs from day 1 after plating and cultured without IGF-1 and FGF-2. e, IC50 values of vemurafenib. Each dot represents one organoid line. Samples were sorted by the IC50 value.
